Patients with systemic lupus erythematosus (SLE) who attain a low disease state have a lower risk of subsequent disease flares and accumulated organ damage, making this state a potential treatment target in clinical trials, a new study suggests. The research was published in an article, “Lupus low disease…
The Childhood Arthritis and Rheumatology Research Alliance (CARRA) has been awarded a three-year $2.4-million grant from the U.S. Centers for Disease Control and Prevention (CDC), which will help efforts to understand the long-term outcomes of children and adolescents with lupus or other rheumatic diseases. The grant is meant…
Progentec, a company developing new diagnostic technologies for chronic conditions, has been awarded $1.7 million to validate its blood biomarker test as an accurate tool for measuring disease activity in systemic lupus erythematosus (SLE), the company announced. The Fast-Track Small Business Innovation Research (SBIR) grant is from the…
Attaining a low disease state — deemed Lupus Low Disease Activity State or LLDAS — has become a major goal for treatment for people with systemic lupus erythematosus. Researchers now have demonstrated that achieving this state not only protects patients from organ damage and improves quality of life,…
The Lupus Research Alliance (LRA) and its affiliate Lupus Therapeutics have expanded a collaboration with Bristol-Myers Squibb to help assess the company’s investigational agent BMS-986165 as a possible treatment for lupus nephritis. The candidate’s effectiveness and safety will be evaluated in a global Phase 2 trial (NCT03943147)…
KZR-616, a selective immunoproteasome inhibitor, is safe, well-tolerated, and effectively reduces disease activity in patients with active systemic lupus erythematosus (SLE), preliminary Phase 1b data show. The findings were presented at the European League Against Rheumatism (EULAR) 2019 Annual Meeting in Geneva, Switzerland, in a poster titled, “…
Mallinckrodt Pharmaceuticals has completed enrollment for its Phase 4 clinical trial evaluating the safety and effectiveness of H.P. Acthar Gel (repository corticotropin injection) in patients with persistently active systemic lupus erythematosus (SLE). The company expects the first results to be available by early 2020. “I am delighted that enrollment is completed, and look forward…
Equillium announced that it is planning to test EQ001, its monoclonal antibody, in a Phase 1b trial as a potential therapy for patients with refractory lupus nephritis, among the most frequent and severe manifestations of lupus and one that can progress to kidney failure. “Our decision to explore EQ001 for…
The Lupus Research Alliance and its affiliate, Lupus Therapeutics, have partnered with Takeda Pharmaceutical to conduct a Phase 1 clinical trial testing Takeda’s investigational antibody TAK-079 for the treatment of systemic lupus erythematosus (SLE) patients. The trial (NCT03724916), which will include approximately 24 participants across the U.S., is for patients with…
Physical fitness, particularly muscle strength and cardiorespiratory fitness, are associated with better quality of life scores in women with systemic lupus erythematosus (SLE), a study reports. The study, “Association of physical fitness components and health-related quality of life in women with systemic lupus erythematosus with mild disease activity,” was…